Boston Scientific agreed to acquire Penumbra in a $14.5 billion cash-and-stock transaction, expanding its portfolio into mechanical thrombectomy and neurovascular devices. The deal gives Boston Scientific access to Penumbra’s Lightning Bolt and Lightning Flash clot‑removal systems and embolization platforms, and it will be funded with cash on hand plus new debt. Company statements noted the acquisition is intended to accelerate entry into high-growth thrombectomy and neurovascular segments and to leverage Boston Scientific’s global commercial reach to scale Penumbra’s devices. The transaction structure allows Penumbra shareholders to elect cash or stock, with roughly 73% of consideration expected in cash and 27% in stock. Penumbra reported strong recent revenue growth (projected Q4 2025 growth ~21–22% and full-year revenue near $1.4 billion), figures Boston Scientific cited when framing strategic rationale. Regulators and investors will watch integration risks and potential antitrust review given overlaps in vascular and neurovascular markets.